ABOUT US
![Image](/wp-content/uploads/2024/06/Bio-Logo-Final-875.png)
ABOUT US
Bioprinting Laboratories Inc. (Bioprinting Labs or BPL) has been exploiting “microarray three-dimensional (3D) bioprinting” technology and developing easy-to-use, disposable pillar/perfusion plates and bioprinted human mini-tissues derived from pluripotent stem cells (a.k.a., organoids). Our main products are injection-molded pillar/perfusion plates, designed for rapid and robust human organoid culture and analysis. These products can be used for 3D cell/tissue culture and predictive screening of compounds in the pharmaceutical, cosmetics, and chemical industries. Our mission is to enhance human safety and health by developing and providing pillar/perfusion plates, bioprinted human organoids on the pillar plates, and related toxicity/efficacy assessment services to serve global in vitro cell-based testing markets.
![Image](/wp-content/uploads/2024/06/bn01.jpg)
Problem & Opportunity
The demand for animal alternatives such as human organoids, bioprinted human tissue constructs, and organ-on-chips is immense. These alternatives are essential for improving the prediction of drug candidate toxicity and efficacy, thereby enhancing the success rate of screening new compounds during preclinical evaluations.
Due to the FDA Modernization Act 2.0, passed in December 2022, there is an enormous need for animal alternatives such as human organoids, bioprinted human tissue constructs, and organ-on-chips to better predict the toxicity and efficacy of new drug candidates and increase the success rate of compound screening in preclinical evaluations. BPL addresses critical customer needs in this market by combining the three alternative models into one pillar/perfusion plate platform. Recently, great advances have been made in organotypic 3D cell/tissue models, such as human organoids, for disease modeling. However, human organoid cultures have been performed on low-throughput platforms such as 6/24-well plates, petri dishes, and spinner flasks, which significantly limit their use in preclinical evaluations. BPL has targeted this bottleneck by developing innovative, microarray 3D bioprinting of human organoids in the pillar/perfusion plate and facilitating robust organoid culture and imaging in situ for predictive compound screening.
Product & Solution
Our products are injection-molded pillar/perfusion plates (e.g., 36PillarPlate, 36PerfusionPlate, 144PillarPlate, 144PerfusionPlate, 384PillarPlate, and 384DeepWellPlate) and their accessories (36PetriLid, 144PetriLid, and LoadingPlate) for 3D cell and organoid cultures, as well as bioprinted human organoids on the pillar plates. Bioprinted human organoids can recapitulate physiologically relevant characteristics of tissues in vivo, thus providing more predictive insight into potential organ-specific toxicity of compounds. This system is cost-effective, high-throughput, and highly reproducible for various cell-based assays, with the capability of up- and down-regulation of specific disease genes in organoids using CRISPRai technology, which is essential for human disease modeling. Additionally, the pillar/perfusion plate system can simulate organ-organ interactions for accurate prediction of drug effects in humans.
Bioprinting Laboratories Inc.
12200 Ford Road, Suite A236
Dallas, Texas 75234
Phone: (214) 730-0707
Email: [email protected]
Contact Us
![Image](/wp-content/uploads/2024/06/Innovation.png)